The development of activatable lytic peptides for targeting triple negative breast cancer

Cytolytic peptides are an emerging class of promising cancer therapeutics shown to overcome drug resistance. They eliminate cancer cells via disruption of the phospholipid bilayer of cell membranes, a mechanism that differentiates it from traditional treatments. However, applications of lytic peptid...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Death Discov
Autors principals: Zhao, Hui, Qin, Xuan, Yang, Dan, Jiang, Yanhong, Zheng, Weihao, Wang, Dongyuan, Tian, Yuan, Liu, Qisong, Xu, Naihan, Li, Zigang
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5629628/
https://ncbi.nlm.nih.gov/pubmed/29263848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddiscovery.2017.37
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars